News & Updates

$Meta-analysis: Lenvatinib boosts survival in refractory thyroid carcinoma with caveat$

Meta-analysis: Lenvatinib boosts survival in refractory thyroid carcinoma with caveat

17 May 2021 by

In the treatment of patients with radioiodine-refractory thyroid carcinoma, lenvatinib may improve their chances of survival but at the cost of a high adverse event rate, according to the results of a meta-analysis.

Meta-analysis: Lenvatinib boosts survival in refractory thyroid carcinoma with caveat

17 May 2021

Tislelizumab trumps docetaxel in pre-treated NSCLC

17 May 2021 by

The anti-PD-1 antibody tislelizumab may help improve patient outcomes vs docetaxel as second- or third-line treatment for advanced or metastatic non–small-cell lung cancer (NSCLC) regardless of histology or PD-L1 expression, interim findings from the phase III RATIONALE 303 study have shown.

Tislelizumab trumps docetaxel in pre-treated NSCLC

17 May 2021

Lumasiran shows therapeutic potential for primary hyperoxaluria type 1

17 May 2021 by

The RNAi* therapeutic agent lumasiran demonstrated favourable clinical outcomes for primary hyperoxaluria type 1 (PH1) in both paediatric and adult patients, according to the results of the phase III ILLUMINATE-A and ILLUMINATE-B trials presented at PAS 2021.

Lumasiran shows therapeutic potential for primary hyperoxaluria type 1

17 May 2021

Osteoporosis medication yields survival benefits in epilepsy

17 May 2021

Adult patients with epilepsy who are initiated on osteoporosis treatment appear to have a reduced 3-year risk of mortality, with bisphosphonates showing a unique protective effect compared with other drugs, according to a study.

Osteoporosis medication yields survival benefits in epilepsy

17 May 2021

Secukinumab shows sustained improvement in paediatric psoriasis

16 May 2021 by

Treatment with either low-dose (LD) or high-dose (HD) secukinumab showed continued improvement in PASI* and IGA** responses up to 24 weeks in children and adolescents with moderate-to-severe plaque psoriasis, according to updated results of a trial presented at PAS 2021.

Secukinumab shows sustained improvement in paediatric psoriasis

16 May 2021

IBD remission may be maintained even after anti-TNF discontinuation

15 May 2021

A large number of patients with inflammatory bowel disease (IBD) remain on remission following discontinuation of antitumour necrosis factor alpha (anti‐TNF) treatment, a study has found. Furthermore, retreatment with the same anti-TNF is usually effective for managing relapse.

IBD remission may be maintained even after anti-TNF discontinuation

15 May 2021

First-line tebentafusp may extend OS in HLA-A*02:01-positive metastatic uveal melanoma

15 May 2021 by

First-line treatment with the bispecific fusion protein tebentafusp demonstrated an overall survival (OS) benefit in patients with human leukocyte antigen (HLA)-A*02:01-positive metastatic uveal melanoma (mUM), according to a phase III, open-label trial presented at AACR 2021.

First-line tebentafusp may extend OS in HLA-A*02:01-positive metastatic uveal melanoma

15 May 2021

Beta-1 selective blockers linked to breast cancer risk

15 May 2021

Women using beta-1 selective blockers may be at increased risk of developing breast cancer, with the association showing a dose-response pattern, according to a study.

Beta-1 selective blockers linked to breast cancer risk

15 May 2021

SGLT2 inhibitors not linked to venous thromboembolism in T2D patients

15 May 2021

Sodium-glucose co-transporter type 2 (SGLT2) inhibitors do not appear to induce an increased rate of venous thromboembolism in patients with type 2 diabetes as compared with dipeptidyl peptidase-4 (DPP-4) inhibitors, which provides reassurance in terms of the thromboembolic safety of the former, according to a recent study.

SGLT2 inhibitors not linked to venous thromboembolism in T2D patients

15 May 2021

Diuretics in hypertension lead to sustained surge in plasma renin activity

14 May 2021 by

Diuretic therapy in primary hypertension results in a sustained increase in plasma renin activity (PRA), which is similar across different diuretics classes and is not related to the average reduction in blood pressure (BP), according to the results of a systematic review and meta-analysis.

Diuretics in hypertension lead to sustained surge in plasma renin activity

14 May 2021

News & Updates

Filter by Specialty:

Specialty:

Meta-analysis: Lenvatinib boosts survival in refractory thyroid carcinoma with caveat

Meta-analysis: Lenvatinib boosts survival in refractory thyroid carcinoma with caveat

Tislelizumab trumps docetaxel in pre-treated NSCLC

Tislelizumab trumps docetaxel in pre-treated NSCLC

Lumasiran shows therapeutic potential for primary hyperoxaluria type 1

Lumasiran shows therapeutic potential for primary hyperoxaluria type 1

Osteoporosis medication yields survival benefits in epilepsy

Osteoporosis medication yields survival benefits in epilepsy

Secukinumab shows sustained improvement in paediatric psoriasis

Secukinumab shows sustained improvement in paediatric psoriasis

IBD remission may be maintained even after anti-TNF discontinuation

IBD remission may be maintained even after anti-TNF discontinuation

First-line tebentafusp may extend OS in HLA-A*02:01-positive metastatic uveal melanoma

First-line tebentafusp may extend OS in HLA-A*02:01-positive metastatic uveal melanoma

Beta-1 selective blockers linked to breast cancer risk

Beta-1 selective blockers linked to breast cancer risk

SGLT2 inhibitors not linked to venous thromboembolism in T2D patients

SGLT2 inhibitors not linked to venous thromboembolism in T2D patients

Diuretics in hypertension lead to sustained surge in plasma renin activity

Diuretics in hypertension lead to sustained surge in plasma renin activity